{"id":832832,"date":"2025-04-02T07:57:07","date_gmt":"2025-04-02T11:57:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\/"},"modified":"2025-04-02T07:57:07","modified_gmt":"2025-04-02T11:57:07","slug":"autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\/","title":{"rendered":"Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">LONDON, April  02, 2025  (GLOBE NEWSWIRE) &#8212; Autolus Therapeutics plc\u00a0(Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in the 24<sup>th<\/sup> Annual Needham Virtual Healthcare Conference.<\/p>\n<p align=\"justify\">Autolus Chief Executive Officer Dr. Christian Itin will present in a Fireside Chat on Wednesday, April 9, 2025 at 9:30am EDT \/ 14:30pm BST.<\/p>\n<p>A webcast of the fireside chat will be available on the \u201cEvents\u201d page in the \u201cInvestor Relations &amp; Media\u201d section of the Company\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=padnO6tZYXiB1xHPtkyrMl7j1qKPUdUU5aPyzcTvuAFzmTxEPvDsrDBc6jopLqGPfXgAOIVDGh-ie9tFbXIOzVbHex2RvbUV5i15a2MfqaWpqrjES-UiBLvxLPsgIZqAkk9f6s53a6LbEeXqmOnYzoRmSprucLc7A7Rg2uKewNDv2jY4NJJsi_w-1c4fVTZt\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.autolus.com\/investor-relations-media\/events\/<\/a>. A replay of the webcast will be archived on the Company\u2019s website for 90 days following the presentation.<\/p>\n<p align=\"justify\">\n        <strong>About Autolus Therapeutics plc<\/strong><br \/>\n        <br \/>Autolus Therapeutics plc\u00a0(Nasdaq: AUTL) is an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved product, AUCATZYL, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pI60Y5xGIDXeJMf1c2HE3AauQR1IcMJyYHe8D9aH_OVawe5ovqFvTJ3349HcOeXvdGOzdLMlkx1zKr1zJ7Qjpg==\" rel=\"nofollow\" target=\"_blank\">www.autolus.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Contact:<\/strong>\n      <\/p>\n<p align=\"justify\">Amanda Cray\u00a0<br \/>+1 617-967-0207\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZzdCVoHplTUrpS4dXJvtZO3eIijpNAk1P5lOQqSPBHUo5AAjHDqCoFz9ybc2NvkhH3tYs9OfJOeNWz-I0bj9CXY29JxvmKFFE9NHDw-Qq38=\" rel=\"nofollow\" target=\"_blank\">a.cray@autolus.com<\/a>\u00a0<\/p>\n<p align=\"justify\">Olivia Manser\u00a0<br \/>+44 7780 471 568\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=20624fgDfNyBMYjcr817QeBegNrwA_gVhq4re5rogbQ83ZCba1BdtwJu8IUTqQDNGeVayb2SkbacgMNoksne4PtkYaQmnJZ82UuFOyzWfhY=\" rel=\"nofollow\" target=\"_blank\">o.manser@autolus.com<\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTEzNCM2ODQ2Mjk0IzIwOTk2MzA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YTBhMTI1YzYtNjZhMy00NzhkLWJkN2ItMTYzMGI4NWU4YzM3LTExMTEyMDEtMjAyNS0wNC0wMi1lbg==\/tiny\/Autolus-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LONDON, April 02, 2025 (GLOBE NEWSWIRE) &#8212; Autolus Therapeutics plc\u00a0(Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in the 24th Annual Needham Virtual Healthcare Conference. Autolus Chief Executive Officer Dr. Christian Itin will present in a Fireside Chat on Wednesday, April 9, 2025 at 9:30am EDT \/ 14:30pm BST. A webcast of the fireside chat will be available on the \u201cEvents\u201d page in the \u201cInvestor Relations &amp; Media\u201d section of the Company\u2019s website at\u00a0https:\/\/www.autolus.com\/investor-relations-media\/events\/. A replay of the webcast will be archived on the Company\u2019s website for 90 days following the presentation. About Autolus Therapeutics plc Autolus Therapeutics plc\u00a0(Nasdaq: AUTL) is an early commercial stage biopharmaceutical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-832832","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LONDON, April 02, 2025 (GLOBE NEWSWIRE) &#8212; Autolus Therapeutics plc\u00a0(Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in the 24th Annual Needham Virtual Healthcare Conference. Autolus Chief Executive Officer Dr. Christian Itin will present in a Fireside Chat on Wednesday, April 9, 2025 at 9:30am EDT \/ 14:30pm BST. A webcast of the fireside chat will be available on the \u201cEvents\u201d page in the \u201cInvestor Relations &amp; Media\u201d section of the Company\u2019s website at\u00a0https:\/\/www.autolus.com\/investor-relations-media\/events\/. A replay of the webcast will be archived on the Company\u2019s website for 90 days following the presentation. About Autolus Therapeutics plc Autolus Therapeutics plc\u00a0(Nasdaq: AUTL) is an early commercial stage biopharmaceutical &hellip; Continue reading &quot;Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-02T11:57:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTEzNCM2ODQ2Mjk0IzIwOTk2MzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference\",\"datePublished\":\"2025-04-02T11:57:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\\\/\"},\"wordCount\":243,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTEzNCM2ODQ2Mjk0IzIwOTk2MzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\\\/\",\"name\":\"Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTEzNCM2ODQ2Mjk0IzIwOTk2MzA=\",\"datePublished\":\"2025-04-02T11:57:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTEzNCM2ODQ2Mjk0IzIwOTk2MzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTEzNCM2ODQ2Mjk0IzIwOTk2MzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - Market Newsdesk","og_description":"LONDON, April 02, 2025 (GLOBE NEWSWIRE) &#8212; Autolus Therapeutics plc\u00a0(Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in the 24th Annual Needham Virtual Healthcare Conference. Autolus Chief Executive Officer Dr. Christian Itin will present in a Fireside Chat on Wednesday, April 9, 2025 at 9:30am EDT \/ 14:30pm BST. A webcast of the fireside chat will be available on the \u201cEvents\u201d page in the \u201cInvestor Relations &amp; Media\u201d section of the Company\u2019s website at\u00a0https:\/\/www.autolus.com\/investor-relations-media\/events\/. A replay of the webcast will be archived on the Company\u2019s website for 90 days following the presentation. About Autolus Therapeutics plc Autolus Therapeutics plc\u00a0(Nasdaq: AUTL) is an early commercial stage biopharmaceutical &hellip; Continue reading \"Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-02T11:57:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTEzNCM2ODQ2Mjk0IzIwOTk2MzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference","datePublished":"2025-04-02T11:57:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\/"},"wordCount":243,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTEzNCM2ODQ2Mjk0IzIwOTk2MzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\/","name":"Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTEzNCM2ODQ2Mjk0IzIwOTk2MzA=","datePublished":"2025-04-02T11:57:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTEzNCM2ODQ2Mjk0IzIwOTk2MzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTEzNCM2ODQ2Mjk0IzIwOTk2MzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/832832","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=832832"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/832832\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=832832"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=832832"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=832832"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}